Plasma fibronectin levels were measured in 33 patients with portal hypertension and c6mpared with modified Child's grading and a previously described prognostic index. Outcome at one year from blood sampling was recorded.
INTRODUCTION
Fibronectin is a glycoprotein which is produced by vascular endothelial cells, fibroblasts and hepatocytes and is thought to function as an opsonin during phagocytosis. Low fibronectin levels have been associated with poor survival in patients with sepsis and trauma2.
Abnormal levels of plasma fibronectin have been found in patients with liver disease. Whereas increased levels have been found in uncomplicated acute hepatitis3'4, low levels were noted in patients with fulminant hepatic failure5. Cirrhotic patients with portal hypertension have been reported to have low levels of plasma fibronectin and it has been suggested that plasma fibronectin level correlates with survival in these patients7.
The aim of this study was to assess plasma fibronectin levels in a variety of portal hypertensive patients, to determine whether plasma fibronectin was related to the severity of liver disease as assessed by Pugh's modification of Child's grading and a previously reported prognostic index9, and to relate plasma fibronectin level to prognosis. (Figure 1 ; r=-0.1).
PATIENTS AND METHODS

Thirty
Three patients died during the index admission for this study, all following a variceal bleed. A further eight patients died during the next year, twenty-two patients survived. Two of these patients died of causes unrelated to their liver disease. The level of plasma fibronectin alone was not an accurate predictor of survival over the following year (Figure 2 ), although the mean plasma fibronectin in one year survivors (337.5mg/1, sem 32.3) was significantly higher than in those patients who died (237.2mg/1, sem 24.6: t=2.47, p<0.01). However plasma fibronectin level and prognostic index together gave good prediction of 1 year survival ( Figure 1 ). Of seven patients who had a plasma fibronectin level of less than 300mg/1 along with a prognostic index of less than 0.5, six died over the next twelve months.
When the 13 patients with repeat plasma fibronectin samples were studied, in nine patients who were stable on both admissions there was no significant difference between the value of prognostic index or plasma fibronectin (mean first fibronectin value 337.5mg/1 sem 67.5; mean second fibronectin 303.3mg/1 sem 39.0; 0.56; p < 0.5).
DISCUSSION
Few portal hypertensive patients in the present study had plasma fibronectin levels below the normal range. Although Foster and colleagues 6 found reduced plasma fibronectin levels in portal hypertension Gluud Nonetheless the combination of low plasma fibronectin and a low prognostic index was associated with a very poor prognosis (Figure 1 ). In this study, stable patients have been included as well as patients who had had a recent variceal bleed and this may explain the reduction in the accuracy of predicting prognosis from 81% to 68% when the prognostic index is used alone. However when prognostic index and plasma fibronectin level are taken together only one of the seven patients with a prognostic index of less than 0.5 and plasma fibronectin level of less than 300mg/1 survived to one year. Since fibronectin acts as an opsonin in the reticuloendothelial system it is not surprising that low levels of this glycoprotein in association with indicators of poor hepatic and renal function are associated with a poor prognosis in portal hypertension.
In conclusion, we have shown that in a heterogenous group of patients with portal hypertension there is a wide range of plasma fibronectin levels, and this may be due to differeing degrees of hepatic decompensation and hepatitis. A recent variceal bleed is associated with lower plasma fibronectin levels.
